安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Yuhan USA – Yuhan USA
Yuhan USA is actively searching for business development and strategic partnership opportunities
- About - Yuhan USA
Yuhan USA is a global business development arm of Yuhan Corporation We are exploring collaborative opportunities and seeking partnerships with global academic research centers, biotech startups, and pharmaceutical companies
- Yuhan – Yuhan USA
At the AACR 2025 Annual Meeting, Yuhan Corporation unveiled promising preclinical results for two of its cancer drug candidates: YH42946, a HER2 EGFR tyrosine kinase inhibitor (TKI), and YH32364, an EGFR×4-1BB bispecific antibody co-developed with ABL Bio
- News - Yuhan USA
Yuhan Presents Preclinical Data on Targeted Therapy YH42946 and Bispecific Immunotherapy YH32364 At the AACR 2025 Annual Meeting, Yuhan Corporation unveiled promising preclinical results for two of its cancer drug candidates: YH42946, a HER2 EGFR tyrosine kinase inhibitor
- Business Development Manager Position Opening – Yuhan USA
As an outpost of Yuhan’s globalization strategy, Yuhan USA is searching for business development and collaboration opportunities in new drug assets and companies that share our drive towards excellence in medicine
- Yuhan’s HER2×4-1BB Bispecific Antibody YH32367 Shows Early Efficacy and . . .
At the AACR 2025 Annual Meeting, Yuhan Corporation presented encouraging interim results from a Phase 1 trial of YH32367, a bispecific antibody targeting HER2 and 4-1BB, in patients with HER2-positive solid tumors refractory or resistant to trastuzumab (Herceptin)
- Yuhan Corporation acquires Progen, a multi-target antibody company . . .
Yuhan Corporation announced on April 5, 2023, that it has signed an investment agreement to secure the largest shareholder stake in Progen Inc , a company with multi-target antibody-based platform technology
- Pipeline - Yuhan USA
Home Pipeline *! elementor - v3 13 3 - 22-05-2023 * elementor-column elementor-spacer-inner{height:var(--spacer-size)} e-con{--container-widget-width:100%} e
|
|
|